Exploring how circular DNA affects treatment resistance in childhood brain tumors.

Investigation of ecDNA as a driver of intratumoral heterogeneity and treatment resistance in high-risk medulloblastoma

NIH-funded research Sanford Burnham Prebys Medical Discovery Institute · NIH-10913331

This study is looking at how a special type of DNA found in tumors might affect how medulloblastoma, a common brain cancer in kids, behaves and responds to treatment, with the hope of finding better ways to help young patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSanford Burnham Prebys Medical Discovery Institute NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-10913331 on NIH RePORTER

What this research studies

This research investigates the role of circular extrachromosomal DNA (ecDNA) in causing variations within tumors and resistance to treatment in medulloblastoma, a common malignant brain tumor in children. By analyzing genetic data from a large group of medulloblastoma patients, the researchers aim to understand how ecDNA contributes to differences in tumor behavior and treatment outcomes. The study employs advanced computational techniques to detect and analyze ecDNA, which may lead to new insights into why some tumors respond poorly to existing therapies.

Who could benefit from this research

Good fit: Ideal candidates for this research are children diagnosed with high-risk medulloblastoma, particularly those under 11 years old.

Not a fit: Patients with non-malignant brain conditions or those diagnosed with low-risk medulloblastoma may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment strategies for children with high-risk medulloblastoma, potentially enhancing survival rates.

How similar studies have performed: While the investigation of ecDNA in medulloblastoma is relatively novel, similar approaches in other cancers have shown promising results in understanding treatment resistance.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancer GenesCancer PatientCancer-Promoting GeneCancers
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.